Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx)

Exclusion Criteria

• •Patients with ICGCTs who are newly diagnosed are excluded from the study.
• •Patients with the diagnosis of mature or immature teratoma in the absence of tumor marker elevations are excluded from the study.
• •Patients who are pregnant or breastfeeding are excluded from the study.
• •Patients who have received previously a high dose chemotherapy regimen and autologous transplant are excluded from this study.
• •Patients who have received gemcitabine, oxaliplatin and/or paclitaxel are excluded from this study.